Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.
Journal of market access & health policy（2022）
摘要
The main AEs among PARPis were hematological. Olaparib was associated with lower AE costs compared to other PARPis.
更多查看译文
关键词
PARP inhibitors,advanced ovarian cancer,adverse event,cost analysis,metastatic breast cancer,platinum-sensitive recurrent ovarian cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要